Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• This invention relates to liquid pharmaceutical compositions of CGRP Receptor antagonists.
• CGRP is a potent neuromodulator that has been implicated in the pathology of cerebrovascular disorders such as migraine and cluster headache.
• elevated levels of CGRP in the jugular vein were found to occur during migraine attacks (Goadsby et al. (1990) Ann. Neurol. 28, 183-187), salivary levels of CGRP are elevated in migraine subjects between (Bellamy et al. (2006) Headache 46, 24-33) and during attacks (Cady et al. (2009) Headache 49, 1258-1266), and CGRP itself has been shown to trigger migrainous headache (Lassen et al. (2002) Cephalalgia 22, 54-61).
• the CGRP receptor antagonist BIBN4096BS has been shown to be effective in treating acute attacks of migraine (Olesen et al. (2004) New Engl. J. Med. 350, 1104-1110) and was able to prevent headache induced by CGRP infusion in a control group (Petersen et al. (2005) Clin. Pharmacol. Ther. 77, 202-213).
• the orally bioavailable CGRP receptor antagonist telcagepant has also shown antimigraine effectiveness in phase III clinical trials (Ho et al. (2008) Lancet 372, 2115-2123; Connor et al. (2009) Neurology 73, 970-977).
• CGRP receptor antagonists may be useful pharmacological agents for disorders that involve CGRP in humans and animals, but particularly in humans. Such disorders include migraine and cluster headache (Doods (2001) Curr. Opin. Invest. Drugs 2, 1261-1268;
• Gastroenterol. 37, 414-422) and cystitis are of particular importance.
• the acute or prophylactic treatment of headache including migraine and cluster headache.
• CGRP receptor antagonists include those disclosed in International Publication WO2012/064910, which published on May 18, 2012, to Merck Sharp & Dohme Corp., which is hereby incorporated by reference in its entirety.
• CGRP receptor antagonists can be formulated for oral dosing as tablets, by using a various methods, including hot melt extrusion and spray drying. Similarly, CGRP receptor antagonists can be formulated for oral dosing as gelatin capsules, as a liquid in a soft capsule, or dry powder or semi-solid in a hard capsule. In addition, CGRP receptor antagonists can be formulated for intravenous dosing.
• the CGRP receptor antagonist liquid pharmaceutical compositions of the instant invention are alcohol-free, low volume liquid pharmaceutical compositions that can be taken without water for the treatment of migraine headache.
• the liquid pharmaceutical compositions of the instant invention have advantages over other liquid compositions of CGRP receptor antagonists in that the active ingredient does not precipitate out upon dilution with saliva. Also, the liquid pharmaceutical compositions of the instant invention have a fast onset of treatment.
• the instant invention relates to liquid pharmaceutical compositions containing CGRP receptor antagonists.
• the CGRP receptor antagonist liquid pharmaceutical compositions of the instant invention are alcohol-free, low volume liquid pharmaceutical compositions that can be taken without water for the treatment of migraine headache. Also disclosed are processes for making said pharmaceutical compositions.
• the instant invention relates to liquid pharmaceutical compositions containing CGRP receptor antagonists.
• the CGRP receptor antagonist liquid pharmaceutical compositions of the instant invention comprise a CGRP receptor antagonist, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
• a particularly effective CGRP receptor antagonist is (S)-N-((3S,5S,6R)-6-methyl- 2-oxo-5-phenyl-l-(2,2,2-trifluoroethyl)piperi
• Compound I is a BCS Class 4 compound, which has low solubility and low permeability (16.6 xlO "6 cm/s). In the liquid pharmaceutical compositions of the instant invention, Compound I stays in solution and does not precipitate immediately upon dilution with saliva.
• the liquid pharmaceutical compositions of the present invention may also contain one or more additional formulation ingredients that may be selected from a wide variety of excipients known in the pharmaceutical formulation art. According to the desired properties of the liquid pharmaceutical compositions, any number of ingredients may be selected, alone or in combination, based upon their known uses in preparing liquid pharmaceutical compositions. Such ingredients include, but are not limited to, flavors, flavor enhancers, sweeteners, preservatives and colorants.
• liquid pharmaceutical compositions as used herein is intended to encompass solutions comprising CGRP receptor antagonists.
• compositions of the present invention are liquid pharmaceutical solutions that comprise a CGRP receptor antagonist and a pharmaceutically acceptable carrier.
• compositions of the present invention are liquid pharmaceutical solutions that comprise (5)-N-((35',55',6i?)-6-methyl-2-oxo-5-phenyl-l-(2,2,2- trifluoroethyl)piperidine-3-yl)-2'-oxo- 1 ⁇ 2', ⁇
• the liquid pharmaceutical solutions comprise an amorphous form of (5)-N-((35 * ,55 * ,6i?)-6-methyl-2-oxo-5-phenyl -(2,2,2-trifluoroethyl)piperidine-3-yl)-2'-o 1 ⁇ 2 5,7-tetrahydrospiro[cyclopenta[3 ⁇ 4]pyridine-6,3'-pyrrolo[2,3-3 ⁇ 4]pyridine]-3-carboxamide.
• the liquid pharmaceutical solutions comprise an anhydrous form of (5)-N-((3 l S,5 l S,6i?)-6-methyl-2-oxo-5-phenyl-l-(2,2,2- trifluoroethyl)piperidine-3-yl)-2'-oxo-l ⁇ 2
• the liquid pharmaceutical solutions comprise a hydrated form of (S)-N-((3S,5S,6R)-6-methyl-2-oxo-5- phenyl-l-(2,2,2-trifluoroethyl)piperidine-3-yl)-2'-oxo- ,2',5,7- tetrahydrospiro[cyclopenta[3 ⁇ 4]pyridine-6,3'-pyrrolo[2,3-3 ⁇ 4]pyridine]-3-carboxamide.
• the pharmaceutical compositions of the present invention are liquid
• pharmaceutical solutions that comprise (5)-N-((35',55',6i?)-6-methyl-2-oxo-5-phenyl-l-(2,2,2- trifluoroethyl)piperidine-3-yl)-2'-oxo-l ⁇ 2',5,7-tetrahydrospiro[cyclopenta[3 ⁇ 4]pyridine-6,3'- pyrrolo[2,3-3 ⁇ 4]pyridine]-3-carboxamide trihydrate.
• the pharmaceutically acceptable carrier comprises a hydrophilic carrier and a water soluble surfactant or mixture of water soluble surfactants.
• the hydrophilic carrier comprises water, glycols, glycol esters and combinations thereof.
• glycol is selected from the group consisting of propylene glycol, PEG and glycerol; glycol ester is selected from the group consisting of glycerol esters and propylene glycol esters of organic acids, or mixtures thereof.
• glycol is selected from the group consisting of propylene glycol, PEG-400, glycerol, or mixtures thereof.
• the organic acids have two or three carbon atoms.
• glycol esters comprise triacetin, triethyl citrate or mixtures thereof.
• the water soluble surfactant is selected from the group consisting of VitE-TPGS, poloxamer, Tween 20, Tween 80, Span 20, and
• the surfactant is VitE-TPGS.
• the surfactant is poloxamer.
• the surfactant is poloxamer with Tween 20.
• the surfactant is poloxamer with Tween 80.
• the surfactant is poloxamer with Span 20.
• the poloxamer is poloxamer 407.
• the surfactant is VitE-TPGS with Tween 20.
• the surfactant is VitE-TPGS with Tween 80.
• the surfactant is VitE-TPGS with Span 20.
• the water soluble surfactant is present in an amount of about 0.1% to 15.0% by weight of the composition. In a class of the invention, the water soluble surfactant is present in an amount of 2.5% to 10% by weight of the composition.
• a suitable water soluble surfactant is VitE-TPGS.
• Another suitable water soluble surfactant is poloxamer 407.
• the CGRP receptor antagonist is present in an amount of about 0.01% to 3.0% by weight of the composition. In a class of the invention, the CGRP receptor antagonist is present in an amount of 0.25% to 2.0% by weight of the
• the CGRP Receptor antagonist is (5)-N- ((35',55',6i?)-6-methyl-2-oxo-5-phenyl-l-(2,2,2-trifluoroethyl)piperidine-3-yl)-2'-oxo- ,2',5,7- tetrahydrospiro[cyclopenta[3 ⁇ 4]pyridine-6,3'-pyrrolo[2,3-3 ⁇ 4]pyridine]-3-carboxamide trihydrate or a salt thereof.
• the volume of the carrier is less than 5 mL.
• an anti-nucleating polymer comprising one or more pharmaceutically acceptable excipients selected from an anti-nucleating polymer, an antioxidant (such as ascorbic acid), a chelating agent (such as ethylenediaminetetraacetic acid (EDTA)), a souring agent, sodium chloride, colors (such as water and organic soluble dyes), sweeteners, flavoring agents or mixtures thereof.
• an antioxidant such as ascorbic acid
• a chelating agent such as ethylenediaminetetraacetic acid (EDTA)
• EDTA ethylenediaminetetraacetic acid
• souring agent sodium chloride
• colors such as water and organic soluble dyes
• sweeteners such as water and organic soluble dyes
• flavoring agents or mixtures thereof comprising one or more pharmaceutically acceptable excipients selected from an anti-nucleating polymer, an antioxidant (such as ascorbic acid), a chelating agent (such as ethylenediaminetetraacetic acid (EDTA)
• the anti-nucleating polymer is selected from the group consisting of Povidone and Kollidone-VA64.
• the souring agent is selected from citric acid, malic acid, lactic acid, sodium citrate and combinations thereof.
• the flavoring agent is selected from the group consisting of mint, peppermint, berries, cherries, menthol and sodium chloride flavoring agents, and combinations thereof.
• the sweetener is selected from the group consisting of sugar, sucralose, aspartame, acesulfame, neotame, and combinations thereof.
• the sweetener is selected from the group consisting of sucralose, aspartame, acesulfame, neotame, and combinations thereof.
• the sweetener is sucralose.
• Exemplifying the invention is a liquid pharmaceutical composition
• a liquid pharmaceutical composition comprising (5)-N-((35 * ,55 * ,6i?)-6-methyl-2-oxo-5-phenyl-l-(2,2,2-trifluoroethyl)piperidine-3-yl)-2'-oxo 1 ⁇ 2 5,7-tetrahydrospiro[cyclopenta[3 ⁇ 4]pyridine-6,3'-pyrrolo[2,3-3 ⁇ 4]pyridine]-3-carboxamide, propylene glycol, PEG-400, Water, VitE-TPGS, Povidone, Sucralose, Menthol, and a peppermint flavor.
• liquid pharmaceutical composition comprising (5)-N-((35',55',6i?)-6-methyl-2-oxo-5-phenyl-l-(2,2,2-trifiuoroethyl)piperidine-3-yl)- 2'-oxo-l ⁇ 2',5,7-tetrahydrospiro[cyclopenta[3 ⁇ 4]pyridine-6,3'-pyrrolo[2,3-3 ⁇ 4]pyridine]-3- carboxamide, propylene glycol, PEG-400, Water, VitE-TPGS, Povidone, Sucralose, Menthol, a peppermint or mint flavor, a souring agent and sodium chloride.
• the liquid pharmaceutical compositions of the instant invention are stable at room temperature. Specifically, the liquid pharmaceutical compositions have good physical and chemical stability at room temperature, in a range of about 25° C ( ⁇ 2° C) to 40° C ( ⁇ 2° C).
• the liquid pharmaceutical compositions of the instant invention have a low viscosity ( ⁇ 0.065 Pa.s) at room temperature. It is desirable to have a liquid pharmaceutical composition with low viscosity that can exit the container quickly. In an embodiment of the invention, the liquid pharmaceutical composition exits the container within 1-10 seconds. In a class of the invention, the liquid pharmaceutical composition exits the container within 1-5 seconds.
• liquid pharmaceutical compositions of the instant invention comprise a level of excipients that are suitable for daily application and the allowance for a single re- administration as needed.
• liquid pharmaceutical compositions of the instant invention are suitable for packaging into multi-dose or unit-dose packages without producing discoloration or degradation.
• the instant invention includes a process of preparing a liquid pharmaceutical composition of (5)-N-((35',55',6i?)-6-methyl-2-oxo-5-phenyl-l-(2,2,2-trifluoroethyl)piperidine-3- yl)-2'-oxo-l ⁇ 2',5,7-tetrahydrospiro[cyclopenta[3 ⁇ 4]pyridine-6,3'-pyrrolo[2,3-3 ⁇ 4]pyridine]-3- carboxamide trihydrate comprising the steps of:
• step (iv) Mixing the solution from step (iii) with the solution of step (ii) by continuous stirring;
• step (v) Dissolving (5)-N-((35',55',6i?)-6-methyl-2-oxo-5-phenyl-l-(2,2,2-trifluoroethyl)piperidine-3- yl)-2'-oxo-l ⁇ 2',5,7-tetrahydrospiro[cyclopenta[3 ⁇ 4]pyridine-6,3'-pyrrolo[2,3-3 ⁇ 4]pyridine]-3- carboxamide thrihydrate in the solution of step (iv) by continuous stirring at room temperature or 40°C until a homogenous solution is formed; (vi) Dissolving one or more excipients in the solution from step (v).
• the liquid pharmaceutical compositions of the present invention may be useful in the therapeutic or prophylactic treatment of disorders associated with CGRP functioning.
• disorders include: migraine and cluster headache; chronic tension type headache; chronic pain; neurogenic inflammation and inflammatory pain; eye pain; tooth pain; non-insulin dependent diabetes mellitus; vascular disorders; inflammation; arthritis; bronchial hyperreactivity; asthma; shock; sepsis; opiate withdrawal syndrome; morphine tolerance; hot flashes in men and women; allergic dermatitis; psoriasis; encephalitis, brain trauma, ischaemia, stroke, epilepsy, and neurodegenerative diseases; skin diseases; neurogenic cutaneous redness, skin rosaceousness and erythema; tinnitus; obesity; inflammatory bowel disease; irritable bowel syndrome; and cystitis.
• the liquid pharmaceutical compositions of the instant invention may be useful in the acute treatment or prophylactic treatment of headache, including migraine and cluster headache.
• the oral liquid formulations provided above are prepared as follows:
• DOGS In order to evaluate the effect of solution volume on exposure, two formulations were tested in dogs; each solution had the same dose of Compound I, but the volume of solution differed.
• the oral solution formulations were delivered to the dogs via syringe to the back of the throat (to simulate swallowing of a small volume liquid solution). No rinse was given with the oral solution formulations.
• 0.75 mL of high and 1.5mL of low drug concentration solutions were used.
• 10 mg dose is given in 20 mL vehicle followed by 15 mL of water.
• PEG 400 solution PEG 400/Orasweet/Water 70%/15%/15% (10 mg dose in 20 mL vehicle followed by 15 mL of water).
• the PEG 400 solution is not suitable for chronic use due to high amount of PEG400. It is only suitable as a single dose in early clinical studies.
• Samples were diluted with 50/50 ACN/water to try to match analytical standard concentration (O.lmg/mL) and analyzed with HPLC.
• the LC conditions used are as follows: 65% 0.1%H3PO4/35%ACN isocratic method, Chromolith SpeedROD RP-18e 50x4.6mm column, UV at 210nm, 40 °C column temperature, 3mL/min flow rate, and lOuL injection volume.
• solution A was diluted 1 :4, the drug concentration remained at the expected level (about 1/5 of the original concentration) for about 30 minutes, and then slowly started to precipitate out.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Neurosurgery (AREA)
• Pain & Pain Management (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Inorganic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (18)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=52666511

Family Applications (1)

Country Status (13)

Cited By (6)

Families Citing this family (3)

Citations (2)

Family Cites Families (5)

• 2014
  • 2014-09-11 KR KR1020227025748A patent/KR20220108207A/ko not_active Ceased
  • 2014-09-11 KR KR1020167006505A patent/KR102337994B1/ko active Active
  • 2014-09-11 KR KR1020217040059A patent/KR20210153745A/ko not_active Ceased
  • 2014-09-11 RU RU2016114537A patent/RU2690006C2/ru active
  • 2014-09-11 EP EP21171525.5A patent/EP3915561A1/en active Pending
  • 2014-09-11 EP EP14844555.4A patent/EP3046923A4/en not_active Withdrawn
  • 2014-09-11 BR BR112016005589A patent/BR112016005589B8/pt active IP Right Grant
  • 2014-09-11 CN CN202011381004.0A patent/CN112545981A/zh active Pending
  • 2014-09-11 AU AU2014318741A patent/AU2014318741B2/en active Active
  • 2014-09-11 CA CA2923426A patent/CA2923426A1/en active Pending
  • 2014-09-11 WO PCT/US2014/055132 patent/WO2015038736A2/en not_active Ceased
  • 2014-09-11 US US15/021,471 patent/US20160220552A1/en not_active Abandoned
  • 2014-09-11 MX MX2016003394A patent/MX384611B/es unknown
  • 2014-09-11 CN CN201480050553.6A patent/CN105531275B/zh not_active Expired - Fee Related
  • 2014-09-11 JP JP2016542091A patent/JP6612234B2/ja active Active
• 2016
  • 2016-02-29 IL IL244356A patent/IL244356B/en active IP Right Grant
  • 2016-03-14 SA SA516370737A patent/SA516370737B1/ar unknown
• 2018
  • 2018-09-10 US US16/125,924 patent/US20190070161A1/en not_active Abandoned
• 2020
  • 2020-12-07 US US17/114,169 patent/US20210330660A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (33)

Also Published As

Similar Documents

Legal Events